vh2022
  • Home
    • About
    • 2022 Committee
    • Privacy Policy
    • Environmental Policy
  • Register
    • Registration Rates
    • Why register
    • Terms & Conditions
    • Accommodation
    • Venue & Location
    • COVID-19 Information
  • Program
    • 2022 Program
    • 2022 Poster Listing
    • Abstract Submission
    • Associated Events
  • Speakers
    • Keynote Speakers 2022
    • Speaker Presentation Assistance
  • Sponsorship
    • Sponsors
    • Why Sponsor
  • Scholarship Opportunities
  • Contact Us
  • Digital Toolkit
  • VH2021 Conference
  • Search
  • Menu Menu
  • Twitter
  • Facebook

Viral Hep 2022

KEYNOTE

SPEAKERS


KEY DEADLINES



Super Early Bird Registration Deadline: Closed


Late Breaker Abstract Submission Deadline: Closed


Early Bird Registration Deadline: Closed


Accommodation Deadline: Closed


Standard Registration Deadline: Closed

JOIN THE MAILING LIST REGISTER

INTERNATIONAL KEYNOTE SPEAKERS

Danjuma Adda, President, World Hepatitis Alliance (WHA)

Danjuma is a Nigerian prince and accomplished public health expert on a mission to raise awareness about Hepatitis and increase access to care. Danjuma is a former Executive Board Member, World Hepatitis Alliance (WHA) for African Region from 2014-2016; founder and past National Coordinator of Civil Society Network on Viral Hepatitis in Nigeria. Danjuma in 2021 assumed the role of President, World Hepatitis Alliance (WHA), UK, the first African to occupy that role in the 15 years history of the organization. The WHA is an international charity organization registered in Switzerland with an operational office in London, with over 340 member organizations in over 100 countries. Danjuma is a Senior Fellow with ASPEN Institute, US; Advisor/Member of the World Health Organizations (WHO) Strategic and Advisory Committee on HIV, Viral Hepatitis and STIs (STAC-HHS); Member AMR Advisory Group of the AMR Patient Alliance; and member of several global networking groups and an accomplished Public Speaker. Danjuma is a Hepatitis B patient, advocate and a voice for poor populations. He was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later. Danjuma wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease, while also promoting other health outcomes such as antimicrobial stewardship and patient safety.

Dr Ed Gane, MBCHB, MD, FRACP, FRSNZ, FAASLD, MNZM, University of Auckland, New Zealand

Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, and Lead Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital. Dr Gane chairs the Ministry of Health committee responsible for HCV elimination and co-wrote the first New Zealand National HepC Action Plan. He is an investigator for many international clinical trials with particular interest in early phase development of new direct acting antiviral therapies against chronic hepatitis C, hepatitis B, NASH and HCC.  He has published over 600 papers in peer-reviewed journals. Dr Gane is current Associate Editor for the Journal of Hepatology In 2011, Dr Gane received the New Zealand Health Research Council (NZHRC) annual Beaven Medal and in 2014, the NZHRC annual Liley Medal. In 2011, Dr. Gane was awarded Member of the Order of New Zealand and in 2017, was named as New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand.

Dr Jeremy Grimshaw, Senior Scientist and Professor, Ottawa Hospital Research Institute and University of Ottawa 

Jeremy Grimshaw a world leader in knowledge translation and implementation science, a rapidly emerging field with substantial impact on health services and policy research. He has devoted his career to bridging the gap between research and clinical care; by encouraging health care professionals to adopt evidence-based research, new research discoveries can be converted into improved population health and efficient health care delivery. His research explores determinants of professional and health-care system performance, evaluates dissemination and implementation strategies to improve care, and builds theoretical and methodological developments. He is a full professor in the Department of Medicine and is also cross-appointed to the School of Epidemiology and Public Health; he is a senior scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute and a Tier 1 Canada Research Chair in Health Knowledge Transfer and Uptake. He is a member of the Canadian Network on Hepatitis C. 

Dr Joseph Tucker, Associate Professor at the London School of Hygiene and Tropical Medicine and at the UNC at Chapel Hill School of Medicine

Joseph D. Tucker is an infectious diseases physician with a special interest in crowdsourcing.  He is an Associate Professor at the London School of Hygiene and Tropical Medicine and at the University of North Carolina at Chapel Hill School of Medicine.  His team’s ongoing research investigates crowdsourcing open calls to increase hepatitis testing and community engagement. His open calls have focused on promoting diagnostics, creating people-friendly health services, and enhancing uptake of vaccines. He has contributed to several World Health Organization guidelines and serves as a member of the TDR Global Working Group. Dr. Tucker has published 419 manuscripts and led grants totaling 15M USD. Joe received his BA from Swarthmore, MD from UNC, AM (RSEA) from Harvard, and PhD from the London School of Hygiene and Tropical Medicine.

LOCAL KEYNOTE SPEAKERS

Troy Combo

Troy has a joint appointment with the Burnet Institute and is employed and based at University of Queensland, Poche Centre for Indigenous Health and is the Aboriginal Program Manager for Eliminate Hepatitis C Australia Partnership: EC Australia. He is a Bundjalung man from the Northern NSW and with over twenty years’ experience. He has held high-level positions and has managed state and national projects working for both State and National peak Aboriginal Health Organisations and Hepatitis Australia.

Carrie Fowlie, CEO Hepatitis Australia

Carrie Fowlie is the CEO of Hepatitis Australia, the national peak body representing the state and territory hepatitis organisations and the interests of 350,000 Australians impacted by viral hepatitis. Carrie has two decades of peak body, policy and social justice experience. Her collaborative work has resulted in policy, programs and law reform consistent with the evidence and the priorities of her constituencies. 

Melinda Hassall, Clinical Nurse Lead at the Australasian Society of HIV,Viral Hepatitis and Sexual Health Medicine (ASHM)

Melinda’s primary focus is identifying opportunities to advance the role of nurses providing BBV and sexual health care through collaboration, education and identification of policy issues to support knowledge translation and implementation of care within our healthcare system. Melinda is a Registered Nurse, a Fellow of the Australian College of Nursing, Australasian Hepatology Association Board Secretary, holds a Graduate Certificate in Health Promotion and a Masters degree in Public Health.

We acknowledge that ASHM offices are located on the land of the Gadigal peoples of the Eora Nation (Sydney Office) and the Turrbal and Jagera/Yuggera peoples (Brisbane Office) who are the Traditional Owners of the lands where both offices are situated. We pay our respects to Elders past and present.


Copyright 2020 by ASHM Conference & Events Division
Scroll to top